Bodybuilding.com settlement
This article was originally published in The Tan Sheet
Executive Summary
Online retailer Bodybuilding.com is required to provide a reproductive toxicity warning to consumers before they purchase select designer steroid products marketed on its website, under the terms of a settlement the firm recently reached with the California-based non-profit Center for Environmental Health. Bodybuilding.com is also required to show the warning before the sale of products containing any of 11 listed ingredients, according to the consent judgment. The 10 products requiring the warning include all the products named in an October 2005 Washington Post article on muscle-building products containing designer steroids and several other products (1"The Tan Sheet" Dec. 5, 2005, p. 9). A monetary penalty of $22,500, to be paid to CEH, is also included in the settlement. San Francisco, Calif.-based Lexington Law Group filed the Prop 65 lawsuit on behalf of CEH July 25 (2"The Tan Sheet" Aug. 7, 2006, p. 10). A hearing on the motion to approve the settlement is set for Oct. 10, according to Lexington Law Group Attorney Howard Hirsh...
You may also be interested in...
Are Designer Steroids Dietary Ingredients? FDA Warning Letter Skirts Issue
Assuming designer steroids are dietary ingredients, they also appear to be new dietary ingredients, FDA writes in a warning letter to the online retailer Bodybuilding.com
Prop 65 Steroid Suit Planned Against Supplements Named In Post
The Center for Environmental Health plans to file a Prop 65 suit in January against 19 dietary supplement manufacturers and retailers for selling products containing anabolic steroids without warning labels, the group announces in a recent notice letter
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.